New GLP-1 pill delivers up to 12% weight loss in 36 weeks

An experimental GLP-1 pill called aleniglipron has demonstrated the ability to help individuals with obesity or overweight achieve up to 12.1% body weight loss within 36 weeks. Unlike injectable options like Wegovy and Ozempic, this small molecule is taken once daily regardless of food intake and offers easier scalable production. Additionally, the weight-loss pill developed by Lilly has officially received approval from the UK regulator, marking a significant step for the oral medication's availability.